The TLR4 antagonist Eritoran protects mice from lethal influenza infection

Nature

Volumn 497, Issue 7450, 2013, Pages 498-502

  Shirey, Kari Ann ^a   Lai, Wendy ^a   Scott, Alison J ^b   Lipsky, Michael ^a   Mistry, Pragnesh ^a   Pletneva, Lioubov M ^c   Karp, Christopher L ^d,h,i   McAlees, Jaclyn ^d   Gioannini, Theresa L ^e,f   Weiss, Jerrold ^e   Chen, Wilbur H ^b   Ernst, Robert K ^b   Rossignol, Daniel P ^g,h   Gusovsky, Fabian ^g   Blanco, Jorge C G ^c   Vogel, Stefanie N ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c Sigmovir Biosystems Inc   (United States)

^d CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g EISAI INC   (United States)

^h BILL AND MELINDA GATES FOUNDATION   (United States)

ⁱ Mt Kemble Corporate Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; ERITORAN; PHOSPHOLIPID; TOLL LIKE RECEPTOR 2;

INFLUENZA; INHIBITION; INJURY; LIGAND; PATHOLOGY; PHOSPHOLIPID; RODENT; SYMPTOM; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; INFLUENZA; LETHALITY; LIGAND BINDING; LUNG INFECTION; LUNG PROTECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION;

ACUTE LUNG INJURY; ANIMALS; ANTIGENS, CD14; ANTIVIRAL AGENTS; CYTOKINES; DISACCHARIDES; FEMALE; INFLUENZA A VIRUS, H1N1 SUBTYPE; LIGANDS; LYMPHOCYTE ANTIGEN 96; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; SUGAR PHOSPHATES; SURVIVAL ANALYSIS; TIME FACTORS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

MUS;

EID: 84878141871     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12118     Document Type: Article

References (30)

1. Imai, Y. et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133, 235-249 (2008).
2. Nhu, Q. M. et al. Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo. Mucosal Immunol. 3, 29-39 (2010).
3. Kalil, A. C. et al. Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis. Shock 36, 327-331 (2011).
4. Mullarkey, M. et al. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304, 1093-1102 (2003).
5. Thompson, W. W. et al. Mortality associated with influenza and respiratory syncytial virus in the United States. J. Am. Med. Assoc. 289, 179-186 (2003).
6. Thompson, W. W. et al. Influenza-associated hospitalizations in the United States. J. Am. Med. Assoc. 292, 1333-1340 (2004).
7. Reid, A. H., Taubenberger, J. K. & Fanning, T. G. The 1918 Spanish influenza: integrating history and biology. Microbes Infect. 3, 81-87 (2001).
8. Taubenberger, J. K., Reid, A. H., Janczewski, T. A. & Fanning, T. G. Integrating historical, clinical and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish influenza virus. Phil. Trans. R. Soc. Lond. B 356, 1829-1839 (2001).
9. Hurt,A. C.,Holien, J. K., Parker, M.,Kelso,A.&Barr, I. G.Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 83, 10366-10373 (2009).
10. McKimm-Breschkin, J. L. et al. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J. Virol. 72, 2456-2462 (1998).
11. Mishin, V. P., Hayden, F. G. & Gubareva, L. V. Susceptibilities of antiviral-resistant influenza viruses tonovel neuraminidase inhibitors. Antimicrob. AgentsChemother. 49, 4515-4520 (2005).
12. Goldblum, S. E., Ding, X., Brann, T. W. & Campbell-Washington, J. Bacterial lipopolysaccharide induces actin reorganization, intercellular gap formation, and endothelial barrier dysfunction in pulmonary vascular endothelial cells: concurrent F-actin depolymerization and new actin synthesis. J. Cell. Physiol. 157, 13-23 (1993).
13. Verhoeven, D., Teijaro, J. T. & Farber, D. L. Pulse-oximetry accurately predicts lung pathology and the immune response during influenza infection. Virology 390, 151-156 (2009).
14. Blanco, J. C. G. et al. Receptor characterization and suceptibility of cotton rats to avian and 2009 pandemic influenza virus strains. J. Virol. 87, 2036-2045 (2013).
15. Ottolini, M. G. et al. The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis. J. Gen. Virol. 86, 2823-2830 (2005).
16. Polakos, N. K. et al. Kupffer cell-dependent hepatitis occurs during influenza infection. Am. J. Pathol. 168, 1169-1178 (2006).
17. Taubenberger, J. K. & Morens, D. M. The pathology of influenza virus infections. Annu. Rev. Pathol. 3, 499-522 (2008).
18. Shirey, K. A. et al. The anti-tumor agent, 5,6-dimethylxanthenone-4- acetic acid (DMXAA), induces IFN-b-mediated antiviral activity in vitro and in vivo. J. Leukoc. Biol. 89, 351-357 (2011).
19. Thomas, K. E.,Galligan, C. L., Newman, R. D., Fish, E. N.&Vogel, S. N.Contribution of interferon-b to themurinemacrophage response to the toll-like receptor 4 agonist, lipopolysaccharide. J. Biol. Chem. 281, 31119-31130 (2006).
20. Kim, H. M. et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist eritoran. Cell 130, 906-917 (2007).
21. Yoon, S. I., Hong, M., Han, G. W.& Wilson, I. A. Crystal structure of solubleMD-1 and its interaction with lipid IVa. Proc. Natl Acad. Sci. USA 107, 10990-10995 (2010).
22. Esparza, G. A., Teghanemt, A., Zhang, D., Gioannini, T. L. & Weiss, J. P. Endotoxinalbumin complexes transfer endotoxin monomers to MD-2 resulting in activation of TLR4. Innate Immun. 18, 478-491 (2012).
23. Gioannini, T. L.,Zhang, D., Teghanemt, A.&Weiss, J. P. An essential role for albumin in the interaction of endotoxin with lipopolysaccharide-binding protein and sCD14 and resultant cell activation. J. Biol. Chem. 277, 47818-47825 (2002).
24. Means, T. K. et al. The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J. Immunol. 163, 6748-6755 (1999).
25. Pauligk, C., Nain, M., Reiling, N., Gemsa, D. & Kaufmann, A. CD14 is required for influenza A virus-induced cytokine and chemokine production. Immunobiology 209, 3-10 (2004).
26. Lee, R. M.,White, M. R. & Hartshorn, K. L. Influenza A viruses upregulate neutrophil Toll-like receptor 2 expression and function. Scand. J. Immunol. 63, 81-89 (2006).
27. Shinya, K. et al. Toll-like receptor pre-stimulation protects mice against lethal infection with high pathogenic influenza viruses. Virol. J. 8, 97-101 (2011).
28. Wong, Y. N. et al. Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. J. Clin. Pharmacol. 43, 735-742 (2003).
29. Tidswell, M. et al. Phase 2 trial of eritoran tetrasodium(E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis. Crit. Care Med. 38, 72-83 (2010).
30. Cohen, J., Opal, S. & Calandra, T. Sepsis studies need new direction. Lancet Infect. Dis. 12, 503-505 (2012).